Autoimmune polyglandular syndrome of adults: current ideas about predictors development of damage of a myocardium and diagnostics of components of a disease

The autoimmune polyglandular syndrome of adults (APS) is characterized by the damage of two and more endocrine glands leading more often to development of their hormonal insufficiency. The basis of most autoimmune endocrine diseases is lymphoid and macrophage infiltration of the target organ. Often in patients with one autoimmune disease, other components of the APS appear after a some time of latent period. Besides defeat organs of endocrine system which are including to the APS also not endocrine organs can be part of autoimmune defeat. Although defeat of cardiovascular system is not included in the structure of the APS, in some clinical cases development of damage of a myocardium in the absence of clinically shown damage of heart against the background of the combined autoimmune endocrine pathology is described. The saved-up clinical this development of damage of a myocardium on the background of autoimmune endocrine insufficiency and also laboratory and instrumental methods of diagnostics is presented in the review at this state. The most promising diagnostic methods for this condition are the determination of autoantibodies to myocardial components and magnetic resonance imaging of the heart. In clinical practice, it is possible to widely use the definition of antibodies to myocardium by indirect immunofluorescence, as well as using standardized immunoenzyme test systems.The saved-up clinical this development of damage of a myocardium on the background of autoimmune endocrine insufficiency and also laboratory and instrumental methods of diagnostics is presented in the review at this state.

1. Van den Driessche A, Eenkhoorn V, Van Gaal L, De Block C. Type 1 diabetes and autoimmune polyglandular syndrome: a clinical review. Neth J Med. 2009;67(11):376-387.

2. Kahaly GJ. Polyglandular autoimmune syndromes. Eur J Endocrinol. 2009;161(1):11-20. doi: 10.1530/EJE-09-0044.

3. Betterle C, Zanchetta R. Update on autoimmune polyendocrine syndromes (APS). Acta Biomed. 2003;74(1):9-33.

4. Ларина А.А., Трошина Е.А., Иванова О.В. Аутоиммунные полигландулярные синдромы взрослых: генетические и иммунологические критерии диагностики. // Проблемы эндокринологии. – 2014. – Т. 60. – № 3. – С. 43-52. [Larina AA, Troshina EA, Ivanova OV. Autoimmune polyglandular syndromes in the adults: the genetic and immunological diagnostic criteria. Problems of endocrinology. 2014;60(3):43-52. (In Russ.)] doi: 10.14341/probl201460343-52.

5. Drvota V, Janson A, Norman C, et al. Evidence for the presence of functional thyrotropin receptor in cardiac muscle. Biochem Biophys Res Commun. 1995;211(2):426-431. doi: 10.1006/bbrc.1995.1831.

6. Cooper DS. Antithyroid drugs. N Engl J Med. 1984;311(21): 1353-1362. doi: 10.1056/nejm198411223112106.

7. Jahns R, Boivin V, Hein L, et al. Direct evidence for a beta1-adrenergic receptor-directed autoimmune attack as a cause of idiopathic dilated cardiomyopathy. J Clin Invest. 2004;113(10): 1419-1429. doi: 10.1172/JCI20149.

8. Sezai A, Hata M, Minami K. Hypertrophic obstructive cardiomyopathy with Schmidt’s syndrome: report of a case. Thorac Cardiovasc Surg. 2010;58(5):314-316. doi: 10.1055/s-0029-1185884.

9. Шульгина В.Ю., Фадеев В.В., Мельниченко Г.А. Поражения миокарда при тиреотоксикозе: особенности течения, исходы, отдаленный прогноз. // Клиническая и экспериментальная тиреоидология. – 2006. – Т. 2. – № 4. – С. 21-30. [Shul’gina VY, Fadeev VV, Mel’nichenko GA. Myocardial lesion in hyperthyroidism: natural history, outcomes, prognosis. Clinical and experimental thyroidology. 2006;2(4):21-30. (In Russ.)] doi: 10.14341/ket20062421-30.

10. Nishimura RA, McGoon MD, Shub C, et al. Echocardiographically documented mitral-valve prolapse. Long-term follow-up of 237 patients. N Engl J Med. 1985;313(21):1305-1309. doi: 10.1056/NEJM198511213132101.

11. Kahaly G, Mohr-kahaly S, Beyer J, Meyer J. Prevalence of myxomatous mitral valve prolapse in patients with lymphocytic thyroiditis. Am J Cardiol. 1995;76(17):1309-1310. doi: 10.1016/s0002-9149(99)80363-4.

12. Channick BJ, Adlin EV, Marks AD, et al. Hyperthyroidism and mitral-valve prolapse. N Engl J Med. 1981;305(9):497-500. doi: 10.1056/NEJM198108273050906.

13. Ma RC, Cheng AY, So WY, et al. Thyrotoxicosis and pulmonary hypertension. Am J Med. 2005;118(8):927-928. doi: 10.1016/j.amjmed.2005.03.038.

14. Siu CW, Zhang XH, Yung C, et al. Hemodynamic changes in hyperthyroidism-related pulmonary hypertension: a prospective echocardiographic study. J Clin Endocrinol Metab. 2007;92(5): 1736-1742. doi: 10.1210/jc.2006-1877.

15. Marvisi M, Brianti M, Marani G, et al. Hyperthyroidism and pulmonary hypertension. Respir Med. 2002;96(4):215-220. doi: 10.1053/rmed.2001.1260.

16. Li JH, Safford RE, Aduen JF, et al. Pulmonary hypertension and thyroid disease. Chest. 2007;132(3):793-797. doi: 10.1378/chest.07-0366.

17. Nathan AW, Longmore DB, Havard CW, Dandona P. The effects of plasma from patients with Graves’ disease on foetal mouse hearts in organ culture. Br J Exp Pathol. 1983;64(5):474-478.

18. Fatourechi V, Edwards WD. Graves’ disease and low-output cardiac dysfunction: implications for autoimmune disease in endomyocardial biopsy tissue from eleven patients. Thyroid. 2000; 10(7):601-605. doi: 10.1089/thy.2000.10.601.

19. Ohwada R, Hotta M, Kimura H, et al. Ampulla cardiomyopathy after hypoglycemia in three young female patients with anorexia nervosa. Intern Med. 2005;44(3):228-233. doi: 10.2169/internalmedicine.44.228.

20. Vanderpump M. Cardiovascular and cancer mortality after radioiodine treatment of hyperthyroidism. J Clin Endocrinol Metab. 2007;92(6):2033-2035. doi: 10.1210/jc.2007-0837.

21. Моисеева О.М., Митрофанова Л.Б., Пахомов А.В., и др. Спорные вопросы диагностики миокардитов. // Сердце: журнал для практикующих врачей. – 2010. – Т. 9. – №4. – С. 234-241. [Moiseeva OM, Mitrofanova LB, Pakhomov AV, et al. Spornye voprosy diagnostiki miokarditov. Serdtse. 2010; 9(4):234-241. (In Russ.)]

22. Deretzi G, Kountouras J, Zavos C, et al. Multiple sclerosis, idiopathic dilated cardiomyopathy, and insulin-dependent diabetes mellitus: a common mechanism of irregular immune regulation. Neurologist. 2011;17(3):172-175. doi: 10.1097/NRL.0b013e3182173552.

23. Gottumukkala RV, Lv H, Cornivelli L, et al. Myocardial infarction triggers chronic cardiac autoimmunity in type 1 diabetes. Sci Transl Med. 2012;4(138):138ra180. doi: 10.1126/scitranslmed.3003551.

24. Дерюгин М.В., Бойцов С.А. Хронические миокардиты. – СПб: ЭЛБИ-СПб; 2005. [Deryugin MV, Boytsov SA. Khronicheskie miokardity. Saint-Petersburg: ELBI-SPb; 2005. (In Russ.)]

25. Pankuweit S, Maisch B. Das Herz bei viralen Infektionen. Internist (Berl). 2010;51(7):836-843. doi: 10.1007/s00108-009-2559-8.

26. Badorff C, Knowlton KU. Dystrophin disruption in enterovirus-induced myocarditis and dilated cardiomyopathy: from bench to bedside. Med Microbiol Immunol. 2004;193(2-3):121-126. doi: 10.1007/s00430-003-0189-7.

27. Rose NR. Myocarditis: infection versus autoimmunity. J Clin Immunol. 2009;29(6):730-737. doi: 10.1007/s10875-009-9339-z.

28. Kawai C. From myocarditis to cardiomyopathy: mechanisms of inflammation and cell death: learning from the past for the future. Circulation. 1999;99(8):1091-1100. doi: 10.1161/01.cir.99.8.1091.

29. Cooper LT. Myocarditis from bench to bedside. New Jersey: Humana Press Totowa; 2003.

30. Поляков В.П., Николаевский Е.Н., Пичко А.Г. Некоронарогенные и инфекционные заболевания сердца. – Самара; 2010. [Polyakov VP, Nikolaevskiy EN, Pichko AG. Nekoronarogennye i infektsionnye zabolevaniya serdtsa. Samara; 2010. (In Russ.)]

31. Aukrust P, Gullestad L, Ueland T, et al. Inflammatory and anti-inflammatory cytokines in chronic heart failure: Potential therapeutic implications. Ann Med. 2009;37(2):74-85. doi: 10.1080/07853890510007232.

32. Mahrholdt H, Wagner A, Deluigi CC, et al. Presentation, patterns of myocardial damage, and clinical course of viral myocarditis. Circulation. 2006;114(15):1581-1590. doi: 10.1161/CIRCULATIONAHA.105.606509.

33. Dillmann WH. Biochemical basis of thyroid hormone action in the heart. Am J Med. 1990;88(6):626-630. doi: 10.1016/0002-9343(90)90530-q.

34. Caforio AL, Tona F, Bottaro S, et al. Clinical implications of anti-heart autoantibodies in myocarditis and dilated cardiomyopathy. Autoimmunity. 2008;41(1):35-45. doi: 10.1080/08916930701619235.

35. Shirani J, Barron MM, Pierre-Louis M-LY, Roberts WC. Congestive heart failure, dilated cardiac ventricles, and sudden death in hyperthyroidism. Am J Cardiol. 1993;72(3):365-368. doi: 10.1016/0002-9149(93)90691-5.

36. Коваленко В.Н., Несукай Е.Г., Чернюк С.В. Миокардит: современный взгляд на этиологию и патогенез заболевания. // Украинский кардиологический журнал. – 2012. – №2. – С. 84-91. [Kovalenko VN, Nesukai YG, Cherniuk SV. Myocarditis: a contemporary look on the etiology and pathogenesis of the disease. Ukrainskiy kardiologicheskiy zhurnal. 2012;(2):84-91. (In Russ.)]

37. Magnusson Y, Wallukat G, Waagstein F, et al. Autoimmunity in idiopathic dilated cardiomyopathy. Characterization of antibodies against the beta 1-adrenoceptor with positive chronotropic effect. Circulation. 1994;89(6):2760-2767. doi: 10.1161/01.cir.89.6.2760.

38. Neumann DA, Lynne Burek C, Baughman KL, et al. Circulating heart-reactive antibodies in patients with myocarditis or cardiomyopathy. J Am Coll Cardiol. 1990;16(4):839-846. doi: 10.1016/s0735-1097(10)80331-6.

39. Caforio ALP, Mahon NJ, Tona F, McKenna WJ. Circulating cardiac autoantibodies in dilated cardiomyopathy and myocarditis: pathogenetic and clinical significance. Eur J Heart Fail. 2002; 4(4):411-417. doi: 10.1016/s1388-9842(02)00010-7.

40. Latif N, Baker CS, Dunn MJ, et al. Frequency and specificity of antiheart antibodies in patients with dilated cardiomyopathy detected using SDS-PAGE and western blotting. J Am Coll Cardiol. 1993;22(5):1378-1384. doi: 10.1016/0735-1097(93)90546-d.

41. Caforio AL, Goldman JH, Baig MK, et al. Cardiac autoantibodies in dilated cardiomyopathy become undetectable with disease progression. Heart. 1997;77(1):62-67. doi: 10.1136/hrt.77.1.62.

42. Greaves K, Oxford JS, Price CP, et al. The prevalence of myocarditis and skeletal muscle injury during acute viral infection in adults. Arch Intern Med. 2003;163(2):165. doi: 10.1001/archinte.163.2.165.

43. Полетаев А.Б. Новые подходы в раннем выявлении патологических изменений в организме человека (иммунохимический скрининг как основа стратегии перехода от лечебной к превентивной медицине): методическое руководство для врачей. – М.: МИЦ Иммункулус; 2011. [Poletaev AB. Novye podkhody v rannem vyyavlenii patologicheskikh izmeneniy v organizme cheloveka (immunokhimicheskiy skrining kak osnova strategii perekhoda ot lechebnoy k preventivnoy meditsine): metodicheskoe rukovodstvo dlya vrachey. Moscow: MITs Immunkulus; 2011. (In Russ.)]

44. Cooper LT, Jr. Myocarditis. N Engl J Med. 2009;360(15): 1526-1538. doi: 10.1056/NEJMra0800028.

45. Morgera T, Di Lenarda A, Dreas L, et al. Electrocardiography of myocarditis revisited: Clinical and prognostic significance of electrocardiographic changes. Am Heart J. 1992;124(2):455-467. doi: 10.1016/0002-8703(92)90613-z.

46. Hundley WG, Bluemke DA, Finn JP, et al. ACCF/ACR/AHA/NASCI/SCMR 2010 expert consensus document on cardiovascular magnetic resonance: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. J Am Coll Cardiol. 2010;55(23):2614-2662. doi: 10.1016/j.jacc.2009.11.011.